Teladoc (TDOC) Misses Q2 EPS by 3c, Revenues Beat; Guides Revs Above
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Teladoc (TDOC) Misses Q2 EPS by 3c, Revenues Beat; Guides Revs Above
August 3, 2018 6:39 AM EDT
Chardan Capital Markets raised its price target on Teladoc (NYSE: TDOC) to $86.00 (from $73.00) while maintaining a Buy rating.
Analyst Steven Wardell commented, "After market close on Wed., TDOC reported revenue and earnings that beat "consensus, and raised its 2018 guide. TDOCs... More
August 2, 2018 9:32 AM EDT
Oppenheimer raised its price target on Teladoc (NYSE: TDOC) to $68.00 (from $59.00) while maintaining a Outperform rating.
Analyst Mohan Naidu commented, "Teladoc Health (as the company has renamed itself) beat our and consensus expectations for revenues and EBITDA at $95M/$2.7M... More
August 2, 2018 8:21 AM EDT
Cantor Fitzgerald raised its price target on Teladoc (NYSE: TDOC) to $52.00 (from $50.00) while maintaining a Neutral rating following the company's 2Q release. Revenue was $94.6 million vs. consensus of $92M. U.S. paid visits grew 41%.
Given the strong growth and including Advance Medical, TDOC... More
August 2, 2018 7:13 AM EDT
Piper Jaffray raised its price target on Teladoc (NYSE: TDOC) to $77.00 (from $55.00) while maintaining an Overweight rating following the company's 2Q earnings report. Total revenue of $94.6M was up 112% on an absolute basis and 39% organically, and beat Consensus estimates of $91.9M. EBITDA of... More
